Breast Cancer Research and Treatment **21**: 227, 1992.
© 1992 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 21

Abarca-Quinones J 63
Alexieva-Figusch J 133
Arriagada R 101

Barnabas-Sohi N 63
Bartels CCM 133
Beaune J 63
Beex LVAM 173
Benraad ThJ 173
Bontenbal M 133
Buehring GC 211

Calaf G 63
Cardoso de Almeida PC 201
Carten J 211
Clark GM 47
Clarke R 35
Comaru-Schally AM 35

Danforth D 139
D'Angelo T 139
Dees A 133
DeMoss E 139
Derazne E 121
DiLonardo A 95
Dion AS 211
Duncan M 139
Dupre G 63

Edgerton SM 111
El-Naggar AK 221

Feuilhade F 63
Findlay P 139
Fisher ER 165
Fletcher WA 193

Gerber L 139
Glatstein E 139
Gorrell C 139
Groot K 35,181

Hilsenbeck SG 47
Hortobagyi GN 3

Johansson H 101

Kahan E 121
Kay MA 83
Klein B 121
Klijn JGM 133
Kloppenborg PWC 173
Koenders PG 173
Koerner FC 111
Korkut E 35
Kouyoumdjian JC 63
Kramar A 101

Lampert M 139
Lapis K 181
Lichter A 139
Lippman ME 139
Lurie H 121

Marcante ML 95
Martino S 55
McDonald H 139
McGuire WL 47
McKnight E 55
Milovanovic S 35,181
Misra LK 221
Muggia FM 27
Muss HB 15

Orrico M 63
Owens MA 47

Pandian MR 47
Parihar AL 221
Pederson WC 217
Pestana CB 201
Pinski J 35
Planting ASTh 133

Ponder KP 83
Posner MC 155

Rakowsky E 121
Ravdin PM 47
Rodenburg CJ 133
Rutqvist LE 101

Sailer SL 147
Schain W 139
Schally AV 35,181
Schwartz A 55
Schwartz LH 111
Siderits R 165
Simon MS 55
Skoog L 101
Smals AGH 173
Steinberg SM 139
Sterns EE 193
Stracher MA 111
Swanson GM 55
Szepeshazi K 35,181

Thor AD 111

van Putten WLJ 133
Vendely P 47
Venuti A 95
Verweij J 133

Williams CJ 211
Wolmark N 155
Woo SLC 83
Wood C 139
Wood WC 111

Yano T 35

Zee B 193

Breast Cancer Research and Treatment **21**: 229-232, 1992.
© 1992 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 21

advanced breast cancer
  endocrine therapy, review 15-26
  outpatient management 27-34
angiosarcoma of the breast
  exclusion of residual angiosarcoma by MRI 221-224
anthrapyrazole CI-941
  in overview of new treatments 7
antiestrogens
  in treatment of advanced breast cancer 18-19
antigens
  epithelial membrane antigen (EMA) in breast fluids and "witch's milk" 211-216
  human milk fat globule antigens and breast cancer prognosis 193-199
  immumnohistochemical markers of breast origin in unknown metastases 201-210
aromatase
  in biopsies and two resulting cell lines 63-75
aromatase inhibitors
  in treatment of advanced breast cancer 19-20
artificial intelligence
  prognostic factor analysis by neural networks 47-53
atypical hyperplasia
  vs. DCIS by cytometric ploidy analysis 165-172
axillary lymph nodes
  number examined as a prognostic factor in node-negative breast cancer 101-109

biological therapy
  overview of new treatments 9-10
bone marrow cells
  as targets for somatic gene therapy 83-93
bone metastases
  book review 147-148
book reviews
  Bone Metastases 147-148
  Plastic and Reconstructive Breast Surgery: An Atlas 217-219
breast fluids
  presence of epithelial membrane antigen (EMA) 211-216
breast reconstruction
  review of *Plastic and Reconstructive Breast Surgery: An Atlas* 217-219
breast-preserving therapy
  for DCIS 155-164

cardiotoxicity
  in low-dose mitoxantrone plus doxorubicin chemotherapy 133-138
cell lines
  two new human mammary lines 63-75
chemical castration
  LH-RH analogs in nude mice 35-45
chemotherapy
  combinations, overview 29-31
  dose intensity 4-5
  low-dose mitoxantrone plus doxorubicin, second-line 133-138
  new drugs 5-8
  overview of new treatments 3-13
  single agent studies 31-32
clinical trials
  non-invasive breast cancer 155-164
conservation treatment
  vs. modified radical mastectomy: pain, motion, and edema 139-145
Cox regression model
  vs. neural networks in prognostic factor analysis 47-53
cytometry
  in distinguishing DCIS from premalignant lesions by DNA content 165-172

DCIS
  see ductal carcinoma in-situ

DNA content
see ploidy
doxorubicin
with low-dose mitoxantrone in second-line therapy 133-138
ductal carcinoma in-situ
aneuploidy determined by cytometric image analysis 165-172
review of non-invasive breast cancer 155-164

EGF receptors
down-regulation by LH-RH ± somatostatin 181-192
endocrine therapy
combinations 21-22
in advanced breast cancer, review 15-26
LH-RH agonists and antagonists in nude mouse model 35-45
new agents 8-9
epidemiology
male breast cancer, race and survival 55-62
estrogen receptor
and prognosis 111-119
and survival from first metastasis 173-180
association with pS2 content 111-119

gene therapy
review 83-93
gross cystic disease fluid protein (GCDFP15)
as a marker of breast origin in unknown metastases 201-210

hepatocytes
as targets for somatic gene therapy 83-93
hobnail lesions
biologic nature, vs. DCIS and premalignant lesions 165-172
hormones
in treatment of advanced breast cancer 15-26
HPV
see human papillomavirus
human milk fat globule (HMFG) antigens
cytoplasmic localization and poor prognosis 193-199
human papillomavirus
evidence for presence in breast tumors 95-100

IGF-I receptors
down-regulation by LH-RH ± somatostatin 181-192
image analysis
in distinguishing DCIS from premalignant lesions by DNA content 165-172
imaging
MRI in exclusion of residual angiosarcoma of the breast 221-224
in situ hybridization
failure to detect PCR-identified papillomavirus in breast tumors 95-100
insulin-like growth factors
see IGF-I
intraductal carcinoma
review of non-invasive breast cancer 155-164
intraductal papilloma
vs. DCIS by cytometric ploidy analysis 165-172

LH-RH
agonist and antagonist in treatment of MXT mouse mammary tumors 181-192
agonists and antagonists, and growth of MCF-7 tumors in nude mice 35-45
sustained delivery of analogs in nude mice 35-45
lobular carcinoma in-situ
review of non-invasive breast cancer 155-164
luteinizing hormone releasing hormone
see LH-RH

magnetic resonance imaging (MRI)
in exclusion of residual angiosarcoma of the breast 221-224
male breast cancer
race and survival, Detroit experience 55-62
markers
see tumor markers
mastectomy
vs. conservation treatment: pain, arm motion, and edema 139-145
MCF-7 cells
LH-RH treatment of nude mouse tumors 35-45

metastases
immunohistochemical markers of breast origin 201-210
metastasis
prognostic factors for survival after first 173-180
mitoxantrone
low-dose, plus doxorubicin, in second-line therapy 133-138
mouse mammary tumor models
estrogen-independent MXT tumors, LH-RH and somatostatin treatment 181-192
mucin marker Mc5
as an indicator of breast origin in unknown metastases 201-210
mucins
polymorphic epithelial mucin (PEM, or EMA) in breast fluids and "witch's milk" 211-216
MXT mouse mammary tumors
and LH-RH, somatostatin treatment 181-192

natural history
DCIS and LCIS 155-164
navelbine
in overview of new treatments 5-7
neural networks
application in prognostic factor analysis 47-53
new drugs
in advanced breast cancer 3-13, 27-34
nodal status
and survival from first metastasis 173-180
non-invasive breast carcinoma
review 155-164
nuclear grade
in distinguishing DCIS from atypical hyperplasia and intraductal papilloma 165-172

papilloma virus
evidence for presence in breast tumors 95-100
PCR
detection of papilloma virus in tumors 95-100
ploidy
in distinguishing DCIS from atypical hyperplasia and intraductal papilloma 165-172
polymerase chain reaction
see PCR
progesterone receptor
and survival from first metastasis 173-180
as a prognostic factor in node-negative breast cancer 101-109
progestins
in treatment of advanced breast cancer 19
prognostic factors
analysis by neural networks 47-53
conventional factors in node-negative breast cancer 101-109
cytoplasmic localization of HMFG antigens 193-199
estrogen receptor 111-119
for survival from first metastasis 173-180
pS2 by immunohistochemistry 111-119
size, number N+, multifocality, and tumor spread in axillary fat in node-positive breast cancer 121-131
pS2
association with ER and tumor grade 111-119
immunohistochemical analysis and prognosis 111-119

quality of life
and treatment of advanced breast cancer 27-34

radiation therapy
and pain, arm motion, and edema 139-145
reconstructive surgery
review of *Plastic and Reconstructive Breast Surgery: An Atlas* 217-219
retroviruses
transduction in somatic gene therapy 83-93
risk factors
lobular carcinoma in-situ 155-164

S-phase
DCIS vs. premalignant lesions 165-172
site of first metastasis
and survival 173-180
size
see tumor size

somatic gene therapy
see gene therapy
somatostatin
analogue in treatment of MXT mouse mammary tumors 181-192
surgery
review of *Plastic and Reconstructive Breast Surgery: An Atlas* 217-219
local excision vs. mastectomy: pain, arm motion, and edema 139-145

T stage
see tumor size
taxol
in overview of new treatments 7
tissue culture
two new human mammary tumor cell lines 63-75
tumor markers
in two new human mammary tumor cell lines 63-75
tumor size
and prognosis in node-negative breast cancer 101-109
prognostic cutoff 3 cm rather than 2 cm in node-positive breast cancer 121-131

"witch's milk"
presence of epithelial membrane antigen (EMA) 211-216